Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Prostate Cancer

  Free Subscription


1 AJR Am J Roentgenol
3 BJU Int
2 BMC Urol
1 Cancer Res
1 Discov Oncol
2 Eur Urol
2 J Urol
1 Magn Reson Imaging
1 Nat Rev Cancer
1 Oncogene
1 PLoS One
1 Proc Natl Acad Sci U S A
3 Prostate
1 Ther Adv Urol
1 Urology

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    AJR Am J Roentgenol

  1. WOO S
    Editorial Comment: Time to Ditch Bone Scans for Prostate Cancer Workup in the Era of PSMA PET/CT?
    AJR Am J Roentgenol. 2022 Jun 29:11. doi: 10.2214/AJR.22.27867.

    BJU Int

  2. DJURHUUS SS, Simonsen C, Toft BG, Thomsen SN, et al
    Exercise Training to Increase Tumor NK Cell Infiltration in Men with Localized Prostate Cancer: an RCT.
    BJU Int. 2022 Jun 26. doi: 10.1111/bju.15842.
    PubMed         Abstract available

  3. FDA approves new agent for the treatment of metastatic prostate cancer.
    BJU Int. 2022;130:3-4.

    Sensible government decisions on funding for imaging can change practice and deliver better care for men with prostate cancer.
    BJU Int. 2022;130 Suppl 1:4.

    BMC Urol

  5. SHIN TY, Lee YS
    Correction to: Robot-assisted radical prostatectomy in the treatment of patients with clinically high-risk localized and locally advanced prostate cancer: single surgeons functional and oncologic outcomes.
    BMC Urol. 2022;22:92.

  6. KIM IE JR, Kim DD, Kim S, Ma S, et al
    Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendations.
    BMC Urol. 2022;22:91.
    PubMed         Abstract available

    Cancer Res

  7. SHANGGUAN X, Ma Z, Yu M, Ding J, et al
    Squalene epoxidase metabolic dependency is a targetable vulnerability in castration-resistant prostate cancer.
    Cancer Res. 2022 Jun 29. pii: 705311. doi: 10.1158/0008-5472.CAN-21-3822.
    PubMed         Abstract available

    Discov Oncol

  8. CHEN X, Ma J, Xu C, Wang L, et al
    Identification of hub genes predicting the development of prostate cancer from benign prostate hyperplasia and analyzing their clinical value in prostate cancer by bioinformatic analysis.
    Discov Oncol. 2022;13:54.
    PubMed         Abstract available

    Eur Urol

  9. MARRA G, Agnello M, Giordano A, Soria F, et al
    Robotic Radical Prostatectomy for Prostate Cancer in Renal Transplant Recipients: Results from a Multicenter Series.
    Eur Urol. 2022 Jun 21. pii: S0302-2838(22)02400.
    PubMed         Abstract available

  10. SAAD F, de Bono J, Barthelemy P, Dorff T, et al
    Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1.
    Eur Urol. 2022 Jun 21. pii: S0302-2838(22)02407.
    PubMed         Abstract available

    J Urol

  11. STINESEN KOLLBERG K, Holmberg E, Josefsson A, Hugosson J, et al
    Prostate-specific antigen (PSA) and biopsy contamination in the Goteborg-1 randomized, population-based, prostate cancer screening trial.
    J Urol. 2022 Jun 30:101097JU0000000000002835. doi: 10.1097/JU.0000000000002835.
    PubMed         Abstract available

    Urological Oncology: Prostate Cancer.
    J Urol. 2022 Jun 27:101097JU0000000000002796. doi: 10.1097/JU.0000000000002796.

    Magn Reson Imaging

  13. TAJIMA T, Akai H, Sugawara H, Furuta T, et al
    Feasibility of accelerated whole-body diffusion-weighted imaging using a deep learning-based noise-reduction technique in patients with prostate cancer.
    Magn Reson Imaging. 2022 Jun 27. pii: S0730-725X(22)00108.
    PubMed         Abstract available

    Nat Rev Cancer

  14. KANAAN Y, Copeland RL
    The link between vitamin D and prostate cancer.
    Nat Rev Cancer. 2022 Jun 27. pii: 10.1038/s41568-022-00493.


  15. DUTTA S, Polavaram NS, Islam R, Bhattacharya S, et al
    Neuropilin-2 regulates androgen-receptor transcriptional activity in advanced prostate cancer.
    Oncogene. 2022 Jun 27. pii: 10.1038/s41388-022-02382.
    PubMed         Abstract available

    PLoS One

  16. LI JR, Wang SS, Chen CS, Cheng CL, et al
    Conventional androgen deprivation therapy is associated with an increased risk of cardiovascular disease in advanced prostate cancer, a nationwide population-based study.
    PLoS One. 2022;17:e0270292.
    PubMed         Abstract available

    Proc Natl Acad Sci U S A

  17. KORSEN JA, Gutierrez JA, Tully KM, Carter LM, et al
    Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer.
    Proc Natl Acad Sci U S A. 2022;119:e2203820119.
    PubMed         Abstract available


  18. BRAY AW, Duan R, Malalur P, Drusbosky LM, et al
    Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration-resistant prostate cancer.
    Prostate. 2022 Jun 29. doi: 10.1002/pros.24400.
    PubMed         Abstract available

  19. CASADO-LLOMBART S, Ajami T, Consuegra-Fernandez M, Carreras E, et al
    Gene variation impact on prostate cancer progression: Lymphocyte modulator, activation, and cell adhesion gene variant contribution.
    Prostate. 2022 Jun 29. doi: 10.1002/pros.24407.
    PubMed         Abstract available

  20. YANAGISAWA T, Kimura T, Hata K, Narita S, et al
    Does castration status affect docetaxel-related adverse events? :Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer.
    Prostate. 2022 Jun 29. doi: 10.1002/pros.24406.
    PubMed         Abstract available

    Ther Adv Urol

  21. GALGANO SJ, West JT, Rais-Bahrami S
    Role of molecular imaging in the detection of localized prostate cancer.
    Ther Adv Urol. 2022;14:17562872221105018.
    PubMed         Abstract available


  22. DELANEY RK, Sisco-Taylor BL, Wang X, Scherr K, et al
    Two Specialists, Two Recommendations: Discordance between Urologists' & Radiation Oncologists' Prostate Cancer Treatment Recommendations.
    Urology. 2022 Jun 26. pii: S0090-4295(22)00512.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.